Special Review Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer

نویسندگان

  • Gordon J. S. Rustin
  • Robert C. Bast
  • Gary J. Kelloff
  • J. Carl Barrett
  • Stephen K. Carter
  • Perry D. Nisen
  • Caroline C. Sigman
  • David R. Parkinson
  • Raymond W. Ruddon
چکیده

Gordon J. S. Rustin, Robert C. Bast, Jr., Gary J. Kelloff, J. Carl Barrett, Stephen K. Carter, Perry D. Nisen, Caroline C. Sigman, David R. Parkinson, and Raymond W. Ruddon Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom; Department of Translational Research, University of Texas M. D. Anderson Cancer Center, Houston, Texas; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; Independent Consultant, New York, New York; Global Oncology Development, Abbott Laboratories, Abbott Park, Illinois; CCS Associates, Mountain View, CA; Amgen, Inc., Thousand Oaks, California; and Johnson & Johnson Corporation, New Brunswick, New Jersey

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

Gordon J. S. Rustin, Robert C. Bast, Jr., Gary J. Kelloff, J. Carl Barrett, Stephen K. Carter, Perry D. Nisen, Caroline C. Sigman, David R. Parkinson, and Raymond W. Ruddon Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom; Department of Translational Research, University of Texas M. D. Anderson Cancer Center, Houston, Texas; Division of Cancer Tre...

متن کامل

FoxP3+ Regulatory T Cells in Peripheral Blood of Patients with Epithelial Ovarian Cancer

Background: Ovarian cancer is the fifth leading cause of death from malignancy in women. CD4 +CD25+FoxP3+ regulatory T (Treg) cells are a subset of T lymphocytes with great inhibitory impact on immune response. Objectives: To investigate the percentage of CD4 +CD25+FoxP3+ regulatory T cells in the peripheral blood of the Iranian patients with epithelial ovarian cancer compared to healthy women ...

متن کامل

The Role of CA-125 in the Management of Ovarian Cancer.

Over more than a decade of clinical use, CA-125 has proven itself to be one of the most useful tumor markers in cancer medicine. The major clinical utility of this serum marker is in following the clinical course of women with known ovarian cancer. Other potential uses of CA-125 include the evaluation of the effectiveness of new antineoplastic agents in this malignancy, and in the modification ...

متن کامل

Successful treatment of ovarian cancer with apatinib combined with chemotherapy

RATIONALE The standard treatment for ovarian cancer is chemotherapy with 2 drugs (taxanes and platinum drugs). However, the traditional combination of the 2 drugs has many adverse effects (AEs) and the cancer cells will quickly become resistant to the drugs. Apatinib is a small-molecule antiangiogenic agent which has shown promising therapeutic effects against diverse tumor types, but it still ...

متن کامل

Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.

The CA 125 II assay on the Elecsys(R) 2010 analyzer was evaluated in an international multicenter trial. Imprecision studies yielded within-run CVs of 0.8-3.3% and between-day CVs of 2.4-10.9%; CVs for total imprecision in the manufacturer's laboratory were 2.4-7.8%. The linear range of the assay extended to at least 4500 kilounits/L (three decades). Interference from triglycerides (10.3 mmol/L...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2004